Juvenile Spondyloarthritis Disease Activity Index Validation in Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis in a Prospective Clinical Trial Setting
Authors' conclusion
These results validate JSpADA as a disease activity measure for children with ERA and jPsA in a prospective clinical trial setting.
Study context
- Population
- Children with enthesitis-related arthritis (ERA) or juvenile psoriatic arthritis (jPsA) in the JUNIPERA trial of secukinumab
- Comparison
- JSpADA vs JADAS10, clinical JADAS10 (cJADAS10) and PGA; across active vs inactive disease and improved, stable or worsening disease
- Primary endpoint
- JSpADA validity: convergent validity (Spearman correlation with JADAS10, cJADAS10, PGA), discriminatory validity (active vs inactive disease; JIA ACR response criteria) and responsiveness to change
- Follow-up
- Week 12 (responsiveness weeks 12 to 52)
Methodological detailsprospective clinical trial setting, placebo-controlled withdrawal, 12 weeks open-label secukinumab then 1:1 randomisation to secukinumab or placebo until flare or week 52
- Prospective clinical trial setting
- Placebo-controlled withdrawal
- 12 weeks open-label secukinumab then 1:1 randomisation to secukinumab or placebo until flare or week 52
Primary result
As reported in the abstract
week 12
Active disease
1.8
mean · SD 1.3
Inactive disease
0.5
mean · SD 0.8
P < 0.001
Further findings
Mean
| Outcome | Improved | Worsening | Stable | P value |
|---|---|---|---|---|
| Responsiveness: change in JSpADA, mean (SD) · weeks 12 to 52Improved vs Worsening | −0.8 (SD 1.1) | 0.4 (SD 1.0) | −0.1 (SD 0.5) | P < 0.001 |
Validity by subtype (ERA vs jPsA)
- Validity results were similar for ERA and jPsA
Original publication
Juvenile Spondyloarthritis Disease Activity Index Validation in Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis in a Prospective Clinical Trial Setting. J Rheumatol. Published 15 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →